Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | NLG207 |
| Trade Name | |
| Synonyms | IT-101|EP0057|CRLX101 |
| Drug Descriptions |
NLG207 (CRLX101) is a nanoparticle conjugated to camptothecin, which inhibits topoisomerase-1 and HIF1-alpha, which may increase sensitivity to chemoradiation, and may result in tumor growth inhibition (PMID: 27784746, PMID: 33390325, PMID: 33632874). |
| DrugClasses | |
| CAS Registry Number | 1883668-61-8 |
| NCIT ID | C62600 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + NLG207 | Bevacizumab NLG207 | 0 | 2 |
| Enzalutamide + NLG207 | Enzalutamide NLG207 | 0 | 1 |
| Fluorouracil + NLG207 + Radiotherapy | Fluorouracil NLG207 Radiotherapy | 0 | 0 |
| NLG207 | NLG207 | 0 | 2 |
| NLG207 + Olaparib | NLG207 Olaparib | 0 | 2 |
| NLG207 + Paclitaxel | NLG207 Paclitaxel | 0 | 0 |